Research status of neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma
10.3760/cma.j.cn115355-20241014-00471
- VernacularTitle:交界可切除胰腺导管腺癌新辅助治疗研究现状
- Author:
Weiwu CHEN
1
;
Yuehong KONG
1
;
Liyuan ZHANG
1
Author Information
1. 苏州大学附属第二医院肿瘤诊疗中心 布拉格治疗中心，苏州 215000
- Publication Type:Journal Article
- Keywords:
Pancreatic neoplasms;
Neoadjuvant therapy;
Immunotherapy
- From:
Cancer Research and Clinic
2025;37(3):232-236
- CountryChina
- Language:Chinese
-
Abstract:
The malignancy of pancreatic cancer is high. Radical resection is the main treatment method for non-metastatic pancreatic ductal adenocarcinoma. Neoadjuvant therapy can improve the surgical resection rate of borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) and prolong the survival of patients. In recent years, a large number of studies have been conducted on neoadjuvant therapy for pancreatic cancer at home and abroad, including radiotherapy, chemotherapy, immunotherapy and combination therapy. This article mainly reviews the current research status of neoadjuvant therapy for BR-PDAC.
